Latest Comments
Lyra Stock Soars 530% on 2025 Trial Win
Lyra Therapeutics’ stock skyrockets 530% in 2025 after positive Phase 3 trial results for LYR-210, targeting chronic rhinosinusitis. Introduction: Lyra’s Meteoric Rise Lyra Therapeutics’ stock[…]